INTRODUCTION
Dietary protein and intravenous infusions of amino acids and dopamine increase renal blood flow and glomerular filtration rate (GFR) in both animals and humans [l-41. In some kidney diseases, however, the effect of amino acids and dopamine on renal haemodynamics has been found to be attenuated [4-71. Also, in renal transplant recipients treated with cyclosporin A (CsA), an abolished or diminished increase in GFR to infusion of dopamine [8, 91 and amino acids, [lo-121 and oral proteins [13, 141 , has been demonstrated. It has been proposed that the nephrotoxic effects of CsA are responsible for the diminished ability of the human transplanted kidney to respond with a rise in GFR to a pharmacological or metabolic stimulus [lo, 13, 141 . In contrast, two studies have found that the amino acid-induced increase in GFR in these patients was comparable to that observed in nonCsA-treated renal transplant recipients [l5], healthy volunteers [ 15, 161 and uninephrectomized control subjects [16] . Furthermore, non-CsA-treated renal transplant recipients seemed to respond adequately to both dopamine and amino acids [17] .
CsA may cause renal tubular injury with vacuolization and dystrophic calcification of tubular cells, interstitial fibrosis and increased urinary levels of tubular brush border enzymes [18] . In normal man, both amino acid and dopamine infusion increased the renal clearance of lithium (CJ, indicating an increase in renal end-proximal tubular delivery [ 19, 203 . Whether CsA treatment has any impact on these dopamine-and amino acid-induced changes in proximal tubular function remains unsettled. The purpose of this study was to investigate whether long-term treatment of renal transplant recipients with low-dose CsA affects the renal haemodynamic and tubular response to infusions of amino acids and dopamine when compared with patients treated without CsA. The renal clearance measurements were taken at nadir CsA blood levels, as each CsA dose may be followed by transient renal hypofiltration C21, 221. (Table I) The study included 16 healthy non-vegetarian, non-diabetic renal transplant recipients who all had a stable graft function with a serum creatinine of less than 130pmol/l for more than 6months. None of the patients had any signs of chronic rejection, or had experienced any episodes of acute rejection since the initial time after the transplantation. Since the time of transplantation eight of the patients had received immunosuppressive treatment with prednisone, azathioprine and low-dose CsA (CsA group). The mean dose of CsA was 2.7 (range 1.5-5.3)mg/ kg. The mean whole-blood trough level of CsA, including its metabolites, was 250 (164-365) ng/ml. The remaining eight patients had never received CsA (non-CsA group), only prednisone and azathioprine. Patients receiving dihydropyridine calcium antagonist and angiotensin-converting enzyme inhibitors were not included because of the potential renal haemodynamic effects of these drugs in CsAtreated patients. The use of non-steroidal antiinflammatory drugs was prohibited in the study period; all other medications remained unchanged.
METHODS

Subjects
Study protocol (Fig. I)
The study protocol was approved by the Ethical Committee of Copenhagen County in accordance with the Helsinki Declaration 11. All patients entered the study after they had given their written informed consent. Renal function and the renal response to intravenous infusion of dopamine and of amino acids were investigated in random order on two separate days with an interval of at least 1 week. The patients adhered to an individualized diet by the use of a diary, starting 3days before each study. In the same period, strenuous exercise and intake of alcohol was prohibited. CLi was used as an index of the proximal tubular outflow of sodium and water [23] . A test dose of lithium carbonate (16.2 mmol, 600 mg) was given at 22.00hours the evening before each study day. The patients fasted from midnight and abstained from smoking and caffeine-containing beverages until completion of each renal clearance study. All morning medication was withheld on both study days. All patients in the CsA group took the latest CsA dose at 20.00 hours the day before each study day. Water diuresis was initiated by an oral water load of 500ml at 07.00hours followed by 200ml every 20min. The patients adopted a supine resting position except for standing briefly when voiding every 20 min. Steady-state condition was considered to be achieved when the urine flow rate approximately equalled the water intake. The effective renal plasma flow (ERPF) and GFR were measured as the renal clearances of '311-hippuran (3.6 MBq) and 99"Tc-diethylenetriaminepenta-acetate (DTPA; 27.0MBq), respectively, by the use of a constant infusion technique with urine collections. After an equilibration period of at least 1 h, there were 12 consecutive renal clearance periods lasting 20 min each: three baseline periods and nine periods with infusion of dopamine (3pgmin-' kg-') or amino acids (3 ml h-' kg-') (Vamino; Pharmacia, Limoges, France; 18 g N/1, 114 g amino acids/l, electrolytefree). In each period, ERPF, GFR, CLi and sodium clearance ( CNa) were calculated from the urinary excretion rate and a plasma sample was drawn in the middle of each period. Arterial blood pressure sphygmomanometry and heart rate were measured in duplicate at baseline and at the end of the infusion.
Analytical methods
Activities of '311-hippuran and 99"Tc-DTPA were determined in a well scintillation counter (Searle 1185; Searle Nuclear Chicago Division, Chicago, IL, U.S.A.). Plasma sodium was measured with a Technicon RA 1000 and urinary sodium with a Technicon RA-XT (Tarrytown, NY, U.S.A.). Lithium in plasma and urine was measured by atomic absorption spectrophotometry (Model 403; Perkin-Elmer, Norwalk, CT, U.S.A.). Whole-blood trough levels of CsA, including its metabolites, were measured by fluorescence polarization immunoassay using an Abbott TDxFLx (Abbott Laboratories, Chicago, IL, U.S.A.). 
Statistical analysis
The baseline values were calculated as the mean of the three renal clearance periods before infusion. The results at 1, 2 and 3 h of infusion were calculated as the mean of the three previous renal clearance periods. The results during both amino acid infusion and dopamine infusion were analysed with analysis of variance (ANOVA) for repeated measures, with the two patient groups as grouping factor and the four l h clearance periods as trial factor. If the ANOVA demonstrated significant differences within or between the two study days, data were further analysed by paired t-test. The null-hypothesis was rejected when P -= 0.05. Unless otherwise indicated, data are presented as means-+SEM. All statistical data were analysed using the statistical software package Systat for Windows version 5 (Systat Inc., Evanston, IL, U.S.A.).
RESULTS
There was no significant difference between the CsA group and the non-CsA group in gender distribution, age, weight or serum creatinine. The time since transplantation was significantly shorter in the CsA group (Table 1) . There was no difference in baseline values of heart rate or MAP between the CsA group and the non-CsA group ( Table 2) . Infusion of amino acids caused a minor increase in heart rate whereas there was no significant change in heart rate during infusion of dopamine (Table 2) . Neither amino acids nor dopamine changed MAP (Table 2) .
There was no significant correlation between either MAP or the whole-blood CsA concentration and the dopamine-and amino-acid induced rise in GFR, ERPF and CLi.
Baseline ERPF and GFR tended to be higher in the non-CsA group, but the difference did not reach statistical significance ( P = 0.08 and P = 0.08, respectively; Fig. 2 ). There was no difference in FF between the CsA group and the non-CsA group (Fig. 2) . Amino acids and dopamine increased ERPF and GFR significantly in both groups, with no significant differences between the groups (Fig.  2) . The maximal increases in ERPF in the non-CsA group and CsA group were 31.0+4.1% and 35.9 & 6.674, respectively, during infusion of dopamine, and 18.7 & 6.7% and 13.9 & 5.3%, respectively, during infusion of amino acids (Fig. 2) . GFR increased in the non-CsA group and CsA group by 15.7 f 3.3% and 18.3 +4.7%, respectively, during infusion of dopamine, and by 18.9+4.5% and 15.0 f 3.7%, respectively, during infusion of amino acids (Fig. 2 ). There was a significant difference between the amino acid-and dopamine-induced change in ERPF (ANOVA, P<O.OOl), but not in GFR. This is reflected by an unchanged FF during infusion of amino acids, and a significant decline in FF during dopamine infusion (Fig. 2) . The relation between individual values of the percentage rise in GFR and baseline GFR is shown in Fig. 3 . Baseline CLi was significantly higher in the nonCsA group when compared with the CsA group ( P <0.01; Table 3 ). CLi increased significantly during infusion of both amino acids and dopamine, with no difference in the response between the two groups ( Table 3) .
There was no significant difference in baseline APR, FPR and FDRNa between the two groups, whereas baseline ADRNa was significantly higher in the non-CsA group (P<O.Ol; Fig. 4) . The almost parallel changes in GFR and CLi during dopamine infusion resulted in an unchanged APR and a significant decrease in FPR in both patient groups (Fig. 4) . ADRN, increased significantly and FDRN, decreased significantly during dopamine infusion with no significant differences between the CsA group and non-CsA group (Fig. 4) . During infusion of amino acids, the ANOVA revealed a significant effect of amino acid infusion on APR (P<O.O5) and FPR (P<O.Ol) with no difference between the two groups (Fig. 4) . However, testing each group individually with t-tests, there was only a significant increase in APR in the first clearance period in the non-CsA group, and a significant decrease in FPR during amino acid infusion in the CsA group (Fig.   4) . Amino acids increased ADRN,, but did not change FDRN,. There were no differences between the CsA group and non-CsA group (Fig. 4) .
There was no significant difference in baseline CNa, FEN, and urine flow rate between the two groups ( Table 3) . Dopamine caused a significant increase in CNa, FEN, and urine flow rate with no differences between the CsA group and non-CsA group ( Table 3) . CNa and FEN, remained unchanged during infusion of amino acids, whereas there was a minor increase in urine flow rate ( Table 3) . Again there was no difference in the response between the CsA group and non-CsA group (Table 3) .
DISCUSSION
The main finding of the present study was that the renal response to infusion of amino acids and dopamine did not differ between the transplanted patients treated with or without CsA. The patients included in the study had a good graft function with a serum creatinine level below 130 pmol/l, and there were no significant differences in the demographic and clinical data between the two groups (except in the time to transplantation since almost all patients transplanted at our department after 1986 receive CsA). Although CsA is known to increase the number of renal transplant recipients with hypertension, the difference in the arterial blood pressure between the two patient groups did not become significant. There was no correlation between blood pressure and the changes in renal haemodynamics and tubular function induced by infusion of dopamine and amino acids.
There was no difference in the increases in GFR and ERPF following infusion of amino acids and dopamine between the patients treated with or without CsA. Furthermore, these responses were comparable with those previously obtained in normal volunteers, investigated by exactly the same renal clearance technique and infusions [19, 201. In these studies, amino acid and dopamine infusion increased GFR by 13% and 9%, respectively, in normal man, compared with the 15-18% increase in GFR in the present transplant recipients. Dopamine increased ERPF by 43% in the normal volunteers [19] and by 31% and 36% in the two groups of transplant recipients, whereas amino acids increased ERPF by 9% in the normal volunteers [20] and by 14-19% in the transplant recipients. Thus, the dopamine-and amino acid-induced changes in renal haemodynamics seem to be preserved in renal transplant recipients with a serum creatinine below 130 pmol/l, independent of concomitant CsA treatment. This is in agreement with some previous studies, where an adequate renal haemodynamic response to amino acids was also demonstrated in CsA-treated renal transplant recipients [15, 161. However, the majority of previous studies in CsAtreated kidney transplanted patients have found either a lack of response or a blunted response to both an oral protein load [13, 141 and infusion of amino acids [10] [11] [12] . Previous studies investigating the renal haemodynamic effect of dopamine have, to our knowledge, all demonstrated a lack of increase in GFR in CsA-treated patients [S, 91, which also is contrary to the present findings. Non-CsA-treated renal transplant recipients seem to respond adequately to both oral proteins [13] and infusions of amino acids [lo, 15, 171 and dopamine [17] , although a single study has reported a lack of GFR increase after oral proteins in hypertensive nonCsA-treated transplant recipients [24] .
Differences in experimental conditions may have contributed to the discrepancy between the studies since a large number of factors can influence the renal effects of dopamine and amino acids. The patients in the present study received a rather low dose of CsA, which may have had a smaller impact on renal haemodynamics compared with studies where the patients received higher doses. The renal clearance measurements in the present study were taken when the patients' whole-blood CsA levels were at their nadir. It has been demonstrated that each administration of CsA is followed by transient renal hypoperfusion [21, 221. Therefore, renal clearance studies in CsA-treated patients may show different results depending on the time interval after the most recent CsA dose. In support of this, an inverse correlation between blood levels of CsA and the renal effects of amino acids has been described [25] . The concomitant medical treatment of the transplant recipients may also influence the study results. Patients receiving antihypertensive medication including dihydropyridine calcium antagonist and angiotensin-converting enzyme inhibitors were not included in the present study. Dihydropyridine calcium antagonist has a vasodilating effect on the renal haemodynamics in CsA-treated renal transplant recipients [22] , and treatment with the angiotensin-converting enzyme inhibitor fosinopril has been demonstrated to increase the renal haemodynamic response to amino acids in hypertensive renal transplant recipients [24] . Two of the patients in the CsA group received diltiazem. However, in contrast to the dihydropyridine calcium antagonist, diltiazem seems not to influence the renal function in CsA-treated patients [26, 271 . The use of nonsteroidal anti-inflammatory drugs was also prohibited in the study period, because it has been demonstrated that indomethacin attenuates the renal response to amino acids [28, 291 . Furthermore, in contrast to the majority of previous studies in renal transplant recipients [9, 11, 12, 141 , the patients in the present study all had a good renal graft function with a serum creatinine below 130pmol. It remains unknown whether the present results can be extrapolated to patients with poor renal function who, for instance, might have an element of chronic CsA nephrotoxicity.
Dopamine and amino acids increase GFR by different mechanisms. Dopamine stimulates intrarenal dopamine receptors, causing vasodilatation of both the afferent and efferent arteriole, and increases GFR predominantly by increasing renal perfusion [19, 301 . The mechanism whereby infusion of amino acids increases GFR has not been fully elucidated. Involvement of glucagon, prostaglandins, a liver hormone, endothelium-derived relaxing factor, renal nerves and the tubuloglomerular feedback mechanisms has been suggested [31] . A single study provided evidence that the amino acid-induced increase in GFR is secondary to an increase in glomerular capillary perfusion pressure [32] . The pathophysiological significance of the renal haemodynamic response to amino acids and dopamine remains uncertain. It has been suggested that GFR is submaximal under normal conditions, and that the acute rise in GFR after a meat meal or intravenous infusion of amino acids or dopamine reflects a renal functional reserve, which should disappear when the number of functioning nephrons are reduced as a consequence of renal hyperfiltration [7, 331. In the present study, quite paradoxically, the patients with the lowest baseline GFR had the highest relative increase in GFR in response to both amino acids and dopamine. This inverse relation is not in accordance with the concept of a renal functional reserve disappearing with a decreasing GFR. Furthermore, some studies in rats and humans have shown that the response to an acute protein load is not related to the number of functioning nephrons and therefore does not reflect a renal functional reserve [2, 31. However, several studies have demonstrated an insufficient renal haemodynamic response to amino acids and dopamine in some renal diseases [4-71, suggesting that a lack of renal response must be considered as an index of renal dysfunction.
Previous studies in humans and experimental animals have shown that CsA to some extent induces renal tubular injuries, as reflected by vacuolization and dystrophic calcification of tubular cells, interstitial fibrosis and increased urinary levels of tubular brush border enzymes [18] . In the present study, tubular function was investigated by the lithium clearance method. The main assumption on which the method is based is that filtered lithium is reabsorbed in the proximal tubule in the same proportion as sodium and water, and that no lithium is reabsorbed or secreted in more distal nephron segments [23, 341 . Although considerable evidence has accumulated in support of the CLi being a reasonably valid index of proximal tubular outflow, recent studies have demonstrated that proximal reabsorption of lithium may lag slightly behind that of water and that some lithium ( < 10%) may be reabsorbed in the loop of Henle [35] . Reabsorption of lithium in the loop of Henle has also been demonstrated during prostaglandin synthesis inhibition [35] . During severe sodium depletion, significant distal tubular reabsorption of lithium has been observed in rats, but not in man [35] . In the present study, however, the patients received a diet with a normal sodium content (150-200 mmol/day), and the use of non-steroidal antiinflammatory drugs was prohibited. The test dose of lithium used in the current study (600mg) has been demonstrated to have a transient natriuretic effect in normal volunteers [36, 371 . Although this may have increased baseline CNa, experimental conditions were similar in both groups of patients.
Treatment with CsA did not affect the amino acid-and dopamine-induced changes in tubular function, as estimated by comparable changes in CLi and calculated renal proximal and distal tubular handling of sodium and water in the two groups of patients. This confirms our previous findings that long-term CsA treatment did not influence the effects of amino acids on tubular function in renal transplant recipients, when measuring renal clearance at nadir CsA blood levels [lS]. Ader et al. [16] likewise found that the acute increase in CLi induced by amino acids in CsA-treated renal transplant recipients was of similar magnitude to that obtained in uninephrectomized control subjects and in normal man.
The similar increase in CLi caused by amino acids and dopamine indicates that both infusions increased proximal tubular outflow to the same extent. The small changes in calculated APR suggest that the increases in CLi were secondary to the increases in GFR. During both infusions, ADRN, increased consistent with a load-dependent response of distal sodium reabsorption [38] . However, FDRN, remained unchanged during infusion of amino acids but was decreased by dopamine. In functional terms, this suggests that the increase in end-proximal tubular delivery during amino acid infusion was compensated by the distal tubule resulting in an unchanged sodium excretion. In the presence of a similar increase in CLi to that with amino acids, the natriuretic response to dopamine may have been caused by inhibition of distal tubular mechanisms which normally increase distal reabsorption in response to an increased sodium load from the proximal tubules. These results are fully comparable to those previously obtained in normal subjects In conclusion, low-dose CsA does not attenuate the renal haemodynamic and tubular response to intravenous infusions of amino acids and of dopamine in renal transplant recipients with a serum creatinine below 130 pmol/l. Furthermore, the amino acid-and dopamine-induced changes in renal haemodynamics and tubular function in the transplant recipients were comparable to those previously observed in normal man.
